
## Anna Ostropolets

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2800686/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study. Lancet Rheumatology, The, 2020, 2, e698-e711.	3.9	117
2	Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study. BMJ, The, 0, , n1435.	6.0	112
3	Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study. Nature Communications, 2020, 11, 5009.	12.8	86
4	COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries. Rheumatology, 2021, 60, SI37-SI50.	1.9	37
5	Metformin Is Associated With a Lower Risk of Atrial Fibrillation and Ventricular Arrhythmias Compared With Sulfonylureas. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009115.	4.8	26
6	Risk of depression, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: a multinational network cohort study. Rheumatology, 2021, 60, 3222-3234.	1.9	20
7	Towards clinical data-driven eligibility criteria optimization for interventional COVID-19 clinical trials. Journal of the American Medical Informatics Association: JAMIA, 2021, 28, 14-22.	4.4	19
8	A scoping review of clinical decision support tools that generate new knowledge to support decision making in real time. Journal of the American Medical Informatics Association: JAMIA, 2020, 27, 1968-1976.	4.4	18
9	Adapting electronic health records-derived phenotypes to claims data: Lessons learned in using limited clinical data for phenotyping. Journal of Biomedical Informatics, 2020, 102, 103363.	4.3	13
10	Bias, Precision and Timeliness of Historical (Background) Rate Comparison Methods for Vaccine Safety Monitoring: An Empirical Multi-Database Analysis. Frontiers in Pharmacology, 2021, 12, 773875.	3.5	13
11	Implementation of the COVID-19 Vulnerability Index Across an International Network of Health Care Data Sets: Collaborative External Validation Study. JMIR Medical Informatics, 2021, 9, e21547.	2.6	11
12	Unraveling COVID-19: A Large-Scale Characterization of 4.5 Million COVID-19 Cases Using CHARYBDIS. Clinical Epidemiology, 2022, Volume 14, 369-384.	3.0	11
13	Incorporation of Korean Electronic Data Interchange Vocabulary into Observational Medical Outcomes Partnership Vocabulary. Healthcare Informatics Research, 2021, 27, 29-38.	1.9	10
14	Characterizing physicians' information needs related to a gap in knowledge unmet by current evidence. JAMIA Open, 2020, 3, 281-289.	2.0	8
15	Characteristics and outcomes of patients with COVID-19 with and without prevalent hypertension: a multinational cohort study. BMJ Open, 2021, 11, e057632.	1.9	8
16	Factors Influencing Background Incidence Rate Calculation: Systematic Empirical Evaluation Across an International Network of Observational Databases. Frontiers in Pharmacology, 2022, 13, 814198.	3.5	8
17	Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus (LEGEND-T2DM): a protocol for a series of multinational, real-world comparative cardiovascular effectiveness and safety studies. BMJ Open, 2022, 12, e057977.	1.9	8
18	Characteristics and Outcomes of Over 300,000 Patients with COVID-19 and History of Cancer in the United States and Spain. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1884-1894.	2.5	6

#	Article	IF	CITATIONS
19	Patient characteristics and antiseizure medication pathways in newly diagnosed epilepsy: Feasibility and pilot results using the common data model in a single-center electronic medical record database. Epilepsy and Behavior, 2022, 129, 108630.	1.7	4
20	Data Consult Service: Can we use observational data to address immediate clinical needs?. Journal of the American Medical Informatics Association: JAMIA, 2021, 28, 2139-2146.	4.4	3
21	Characterizing Anchoring Bias in Vaccine Comparator Selection Due to Health Care Utilization With COVID-19 and Influenza: Observational Cohort Study. JMIR Public Health and Surveillance, 2022, 8, e33099.	2.6	2
22	Potential Role of Clinical Trial Eligibility Criteria in Electronic Phenotyping. Studies in Health Technology and Informatics, 2021, 281, 148-152.	0.3	1
23	Characteristics and outcomes of COVID-19 patients with COPD from the United States, South Korea, and Europe. Wellcome Open Research, 0, 7, 22.	1.8	1
24	Characteristics and outcomes of COVID-19 patients with COPD from the United States, South Korea, and Europe. Wellcome Open Research, 0, 7, 22.	1.8	0